BI Asset Management Fondsmaeglerselskab A S Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

BI Asset Management Fondsmaeglerselskab A S boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 37.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,755 shares of the biopharmaceutical company's stock after purchasing an additional 3,232 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Alnylam Pharmaceuticals were worth $2,766,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in the company. Tidal Investments LLC lifted its stake in Alnylam Pharmaceuticals by 75.1% in the third quarter. Tidal Investments LLC now owns 20,544 shares of the biopharmaceutical company's stock worth $5,650,000 after acquiring an additional 8,811 shares during the period. American Trust bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $309,000. Versant Capital Management Inc raised its stake in Alnylam Pharmaceuticals by 77.6% in the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 83 shares in the last quarter. Everence Capital Management Inc. purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth $593,000. Finally, Nordea Investment Management AB boosted its position in Alnylam Pharmaceuticals by 6.7% during the 4th quarter. Nordea Investment Management AB now owns 10,188 shares of the biopharmaceutical company's stock valued at $2,417,000 after acquiring an additional 637 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded up $8.95 during trading on Friday, reaching $251.56. 835,531 shares of the company traded hands, compared to its average volume of 877,672. Alnylam Pharmaceuticals, Inc. has a 12-month low of $143.00 and a 12-month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The stock has a market cap of $32.72 billion, a P/E ratio of -115.93 and a beta of 0.30. The firm's fifty day simple moving average is $247.37 and its 200 day simple moving average is $256.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ALNY. HC Wainwright reaffirmed a "buy" rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Scotiabank boosted their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 31st. Sanford C. Bernstein decreased their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Finally, Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a research report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $315.58.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 1,213 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the sale, the chief executive officer now owns 81,526 shares of the company's stock, valued at approximately $20,802,989.42. This represents a 1.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 59,984 shares of company stock worth $16,864,347 in the last quarter. Corporate insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.